Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
20–64
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female patients at least 20 years of age and less than 65 years old
Patients must be inpatients during the study
Patients must have a diagnosis of schizophrenia as per the DSM-IV, as determined by the investigator
Patients must be considered by the investigator to be clinically agitated and to be clinically appropriate candidates for the treatment with intramuscular (IM) medication
Patients must have a minimum total score of greater than or equal to 14 on the 5 items of the PANSS-EC and at least one individual item score of greater than or equal to 4 using the 1-7 scoring system, prior to the first IM injection of study drug
You may not be if
Serious, unstable illnesses such that death is anticipated within 1 year or intensive care unit hospitalization for the disease is anticipated within 6 months. This includes hepatic (specifically any degree of jaundice), renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic diseases
Known history of seizures; however, a patient whose etiology is identifiable and has been resolved may be enrolled
Known history of diabetes mellitus, complications of diabetes mellitus, or potential diabetes mellitus as defined by patients with single blood glucose measurement based on site tests; patients with values greater than or equal to 140 mg/dL (non-fasting) or greater than or equal to 110 mg/dL (fasting) must be excluded from the study
History of allergic reaction or intolerance to olanzapine
Have received treatment with psychostimulants or reserpine within 1 week prior to study drug administration
